ESC-HFA 2023 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sits down with PI, Dr Robert J Mentz (Duke University of Medicine, US) to discuss the findings of the PARAGLIDE-HF trial (NCT03988634).

The PARAGLIDE-HF aimed to evaluate the effects of sacubitril/valsartan compared to valsartan on changes in NT-proBNP, safety and tolerability in HFpEF patients who have experienced a WHF event (HFpEF decompensation) and have been stabilized and initiated treatment within 30 days post-decompensation. 
The results presented at Heart Failure 2023 provide additional evidence supporting the potential treatment benefits of sacubitril/valsartan in heart failure patients with EF>40%, particularly those with EF below normal. 

Explore more content from the ESC Heart Failure 2023 Late-breaking Science Collection.

Recorded on-site at HFA 2023, Prague. 

Editor: Mirjam Boros

Video Specialist: Tom Green